164 related articles for article (PubMed ID: 38067624)
1. Target Screen of Anti-Hyperuricemia Compounds from Cortex Fraxini In Vivo Based on ABCG2 and Bioaffinity Ultrafiltration Mass Spectrometry.
Huang X; Dong W; Luo X; Xu L; Wang Y
Molecules; 2023 Dec; 28(23):. PubMed ID: 38067624
[TBL] [Abstract][Full Text] [Related]
2. Protective effects of cortex fraxini coumarines against oxonate-induced hyperuricemia and renal dysfunction in mice.
Li JM; Zhang X; Wang X; Xie YC; Kong LD
Eur J Pharmacol; 2011 Sep; 666(1-3):196-204. PubMed ID: 21620826
[TBL] [Abstract][Full Text] [Related]
3. (1)H NMR and MS based metabolomics study of the therapeutic effect of Cortex Fraxini on hyperuricemic rats.
Wang Y; Zhao M; Xin Y; Liu J; Wang M; Zhao C
J Ethnopharmacol; 2016 Jun; 185():272-81. PubMed ID: 27001626
[TBL] [Abstract][Full Text] [Related]
4. ABCG2 as a therapeutic target candidate for gout.
Fujita K; Ichida K
Expert Opin Ther Targets; 2018 Feb; 22(2):123-129. PubMed ID: 29264928
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetic study of the main components of cortex fraxini after oral administration in normal and hyperuricemic rats.
Wang Y; Zhao M; Ye H; Shao Y; Yu Y; Wang M; Zhao C
Biomed Chromatogr; 2017 Aug; 31(8):. PubMed ID: 28084025
[TBL] [Abstract][Full Text] [Related]
6. The Role of ABCG2 in the Pathogenesis of Primary Hyperuricemia and Gout-An Update.
Eckenstaler R; Benndorf RA
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206432
[TBL] [Abstract][Full Text] [Related]
7. Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout.
Toyoda Y; Pavelcová K; Bohatá J; Ješina P; Kubota Y; Suzuki H; Takada T; Stiburkova B
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669292
[TBL] [Abstract][Full Text] [Related]
8. ABCG2 dysfunction increases the risk of renal overload hyperuricemia.
Matsuo H; Takada T; Nakayama A; Shimizu T; Sakiyama M; Shimizu S; Chiba T; Nakashima H; Nakamura T; Takada Y; Sakurai Y; Hosoya T; Shinomiya N; Ichida K
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):266-74. PubMed ID: 24940678
[TBL] [Abstract][Full Text] [Related]
9. Research on the pharmacodynamics and mechanism of Fraxini Cortex on hyperuricemia based on the regulation of URAT1 and GLUT9.
Zhou Y; Zhang X; Li C; Yuan X; Han L; Li Z; Tan X; Song J; Wang G; Jia X; Feng L; Qiao X; Liu J
Biomed Pharmacother; 2018 Oct; 106():434-442. PubMed ID: 29990831
[TBL] [Abstract][Full Text] [Related]
10. [Recent progress and prospects for research on urate efflux transporter ABCG2].
Ichida K
Nihon Rinsho; 2014 Apr; 72(4):757-65. PubMed ID: 24796111
[TBL] [Abstract][Full Text] [Related]
11. Functional Characterization of Clinically-Relevant Rare Variants in
Toyoda Y; Mančíková A; Krylov V; Morimoto K; Pavelcová K; Bohatá J; Pavelka K; Pavlíková M; Suzuki H; Matsuo H; Takada T; Stiburkova B
Cells; 2019 Apr; 8(4):. PubMed ID: 31003562
[TBL] [Abstract][Full Text] [Related]
12. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload.
Matsuo H; Nakayama A; Sakiyama M; Chiba T; Shimizu S; Kawamura Y; Nakashima H; Nakamura T; Takada Y; Oikawa Y; Takada T; Nakaoka H; Abe J; Inoue H; Wakai K; Kawai S; Guang Y; Nakagawa H; Ito T; Niwa K; Yamamoto K; Sakurai Y; Suzuki H; Hosoya T; Ichida K; Shimizu T; Shinomiya N
Sci Rep; 2014 Jan; 4():3755. PubMed ID: 24441388
[TBL] [Abstract][Full Text] [Related]
13. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout.
Woodward OM; Köttgen A; Coresh J; Boerwinkle E; Guggino WB; Köttgen M
Proc Natl Acad Sci U S A; 2009 Jun; 106(25):10338-42. PubMed ID: 19506252
[TBL] [Abstract][Full Text] [Related]
14. Paeonia × suffruticosa Andrews leaf extract and its main component apigenin 7-O-glucoside ameliorate hyperuricemia by inhibiting xanthine oxidase activity and regulating renal urate transporters.
Zhang Y; Li Y; Li C; Zhao Y; Xu L; Ma S; Lin F; Xie Y; An J; Wang S
Phytomedicine; 2023 Sep; 118():154957. PubMed ID: 37478683
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia.
Pálinkás M; Szabó E; Kulin A; Mózner O; Rásonyi R; Juhász P; Nagy K; Várady G; Vörös D; Zámbó B; Sarkadi B; Poór G
Clin Exp Med; 2023 Aug; 23(4):1277-1284. PubMed ID: 35939175
[TBL] [Abstract][Full Text] [Related]
16. Intestinal uric acid excretion contributes to serum uric acid decrease during acute gout attack.
Zhao T; Cao L; Lin C; Xu R; Du X; Zhou M; Yang X; Wan W; Zou H; Zhu X
Rheumatology (Oxford); 2023 Dec; 62(12):3984-3992. PubMed ID: 37042723
[TBL] [Abstract][Full Text] [Related]
17. The prevalence of the gout-associated polymorphism rs2231142 G>T in ABCG2 in a pregnant female Filipino cohort.
Roman Y; Tiirikainen M; Prom-Wormley E
Clin Rheumatol; 2020 Aug; 39(8):2387-2392. PubMed ID: 32107664
[TBL] [Abstract][Full Text] [Related]
18. Differential gene expression of ABCG2, SLC22A12, IL-1β, and ALPK1 in peripheral blood leukocytes of primary gout patients with hyperuricemia and their comorbidities: a case-control study.
Natsuko PD; Laura SC; Denise CC; Lucio VR; Carlos AS; Fausto SM; Ambar LM
Eur J Med Res; 2022 May; 27(1):62. PubMed ID: 35505381
[TBL] [Abstract][Full Text] [Related]
19. Epistatic interaction between PKD2 and ABCG2 influences the pathogenesis of hyperuricemia and gout.
Dong Z; Zhou J; Jiang S; Li Y; Zhao D; Yang C; Ma Y; He H; Ji H; Jin L; Zou H; Wang J
Hereditas; 2020 Jan; 157(1):2. PubMed ID: 32000861
[TBL] [Abstract][Full Text] [Related]
20. ABCG2/BCRP dysfunction as a major cause of gout.
Matsuo H; Takada T; Ichida K; Nakamura T; Nakayama A; Suzuki H; Hosoya T; Shinomiya N
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1117-28. PubMed ID: 22132966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
